# Hubspot Inc: financial statements, quarterly

HUBS · NYSE · CIK 1404655 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/hubs.md) · [Financials](/companies/hubs/financials.md) · [Filings](/companies/hubs/filings.md) · [Insiders](/companies/hubs/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/hubs/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [558](/filings/0000950170-24-122373.md) | [582 d](/filings/0001193125-26-046646.md) | [617](/filings/0000950170-25-067055.md) | [637](/filings/0000950170-25-104104.md) | [670](/filings/0001193125-25-267056.md) | [703 d](/filings/0001193125-26-046646.md) | [714](/filings/0001193125-26-212122.md) | [761](/filings/0001193125-26-335232.md) | [810](/filings/0001193125-25-267056.md) | [847 d](/filings/0001193125-26-046646.md) | [881](/filings/0001193125-26-212122.md) | [912](/filings/0001193125-26-335232.md) |
| Cost of revenue | $m | [85.6](/filings/0000950170-24-122373.md) | [87.4 d](/filings/0001193125-26-046646.md) | [95.1](/filings/0000950170-25-067055.md) | [95.5](/filings/0000950170-25-104104.md) | [99.3](/filings/0001193125-25-267056.md) | [103 d](/filings/0001193125-26-046646.md) | [115](/filings/0001193125-26-212122.md) | [122](/filings/0001193125-26-335232.md) | [134](/filings/0001193125-25-267056.md) | [138 d](/filings/0001193125-26-046646.md) | [146](/filings/0001193125-26-212122.md) | [161](/filings/0001193125-26-335232.md) |
| Gross profit | $m | [472](/filings/0000950170-24-122373.md) | [494 d](/filings/0001193125-26-046646.md) | [522](/filings/0000950170-25-067055.md) | [542](/filings/0000950170-25-104104.md) | [570](/filings/0001193125-25-267056.md) | [600 d](/filings/0001193125-26-046646.md) | [599](/filings/0001193125-26-212122.md) | [639](/filings/0001193125-26-335232.md) | [676](/filings/0001193125-25-267056.md) | [709 d](/filings/0001193125-26-046646.md) | [735](/filings/0001193125-26-212122.md) | [751](/filings/0001193125-26-335232.md) |
| Research and development | $m | [157](/filings/0000950170-24-122373.md) | [163 d](/filings/0001193125-26-046646.md) | [176](/filings/0000950170-25-067055.md) | [198](/filings/0000950170-25-104104.md) | [191](/filings/0001193125-25-267056.md) | [214 d](/filings/0001193125-26-046646.md) | [220](/filings/0001193125-26-212122.md) | [237](/filings/0001193125-26-335232.md) | [228](/filings/0001193125-25-267056.md) | [221 d](/filings/0001193125-26-046646.md) | [234](/filings/0001193125-26-212122.md) | [226](/filings/0001193125-26-335232.md) |
| Operating income | $m | [(18.6)](/filings/0000950170-24-122373.md) | [(23.2) d](/filings/0001193125-26-046646.md) | [(23.2)](/filings/0000950170-25-067055.md) | [(23.9)](/filings/0000950170-25-104104.md) | [(9.6)](/filings/0001193125-25-267056.md) | [(10.8) d](/filings/0001193125-26-046646.md) | [(27.5)](/filings/0001193125-26-212122.md) | [(24.6)](/filings/0001193125-26-335232.md) | [11.2](/filings/0001193125-25-267056.md) | [48.2 d](/filings/0001193125-26-046646.md) | [27.9](/filings/0001193125-26-212122.md) | [43.3](/filings/0001193125-26-335232.md) |
| Interest expense | $m | [1.0](/filings/0000950170-23-061183.md) | [1.0 d](/filings/0000950170-24-015277.md) | [0.9](/filings/0000950170-24-057772.md) | [0.9](/filings/0000950170-24-092843.md) | [0.9](/filings/0001193125-25-267056.md) | [0.9 d](/filings/0001193125-26-046646.md) | [0.6](/filings/0001193125-26-212122.md) | [0.2](/filings/0001193125-26-335232.md) | [0.0](/filings/0001193125-25-267056.md) | [0.0 d](/filings/0001193125-26-046646.md) | [0.2](/filings/0001193125-26-212122.md) | [0.4](/filings/0001193125-26-335232.md) |
| Income tax | $m | [(1.4)](/filings/0000950170-24-122373.md) | [4.4 d](/filings/0001193125-26-046646.md) | [1.8](/filings/0000950170-25-067055.md) | [11.8](/filings/0000950170-25-104104.md) | [2.5](/filings/0001193125-25-267056.md) | [8.0 d](/filings/0001193125-26-046646.md) | [11.9](/filings/0001193125-26-212122.md) | [(2.2)](/filings/0001193125-26-335232.md) | [6.6](/filings/0001193125-25-267056.md) | [7.2 d](/filings/0001193125-26-046646.md) | [6.7](/filings/0001193125-26-212122.md) | [6.2](/filings/0001193125-26-335232.md) |
| Net income | $m | [(3.6)](/filings/0000950170-24-122373.md) | [(12.4) d](/filings/0001193125-26-046646.md) | [5.9](/filings/0001193125-25-267056.md) | [(14.4)](/filings/0001193125-25-267056.md) | [8.1](/filings/0001193125-25-267056.md) | [5.0 d](/filings/0001193125-26-046646.md) | [(21.8)](/filings/0001193125-26-335232.md) | [(3.3)](/filings/0001193125-26-335232.md) | [16.5](/filings/0001193125-25-267056.md) | [54.4 d](/filings/0001193125-26-046646.md) | [32.6](/filings/0001193125-26-335232.md) | [43.3](/filings/0001193125-26-335232.md) |
| Diluted EPS | $ per share | [(0.07)](/filings/0000950170-24-122373.md) | not reported | [0.12](/filings/0000950170-25-067055.md) | [(0.28)](/filings/0000950170-25-104104.md) | [0.16](/filings/0001193125-25-267056.md) | not reported | [(0.42)](/filings/0001193125-26-212122.md) | [(0.06)](/filings/0001193125-26-335232.md) | [0.31](/filings/0001193125-25-267056.md) | not reported | [0.62](/filings/0001193125-26-212122.md) | [0.86](/filings/0001193125-26-335232.md) |
| Basic EPS | $ per share | [(0.07)](/filings/0000950170-24-122373.md) | not reported | [0.12](/filings/0000950170-25-067055.md) | [(0.28)](/filings/0000950170-25-104104.md) | [0.16](/filings/0001193125-25-267056.md) | not reported | [(0.42)](/filings/0001193125-26-212122.md) | [(0.06)](/filings/0001193125-26-335232.md) | [0.31](/filings/0001193125-25-267056.md) | not reported | [0.62](/filings/0001193125-26-212122.md) | [0.86](/filings/0001193125-26-335232.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [536](/filings/0000950170-24-122373.md) | [388](/filings/0000950170-25-018873.md) | [448](/filings/0000950170-25-067055.md) | [798](/filings/0000950170-25-104104.md) | [410](/filings/0001193125-25-267056.md) | [513](/filings/0001193125-26-046646.md) | [625](/filings/0001193125-26-212122.md) | [601](/filings/0001193125-26-335232.md) | [614](/filings/0001193125-25-267056.md) | [882](/filings/0001193125-26-335232.md) | [944](/filings/0001193125-26-212122.md) | [958](/filings/0001193125-26-335232.md) |
| Current assets | $m | [1,975](/filings/0000950170-23-061183.md) | [1,872](/filings/0000950170-25-018873.md) | [1,985](/filings/0000950170-24-057772.md) | [2,236](/filings/0000950170-24-092843.md) | [2,439](/filings/0000950170-24-122373.md) | [2,634](/filings/0001193125-26-046646.md) | [2,614](/filings/0000950170-25-067055.md) | [2,310](/filings/0000950170-25-104104.md) | [2,114](/filings/0001193125-25-267056.md) | [2,450](/filings/0001193125-26-335232.md) | [2,442](/filings/0001193125-26-212122.md) | [2,127](/filings/0001193125-26-335232.md) |
| Total assets | $m | [2,816](/filings/0000950170-23-061183.md) | [3,071](/filings/0000950170-25-018873.md) | [3,193](/filings/0000950170-24-057772.md) | [3,356](/filings/0000950170-24-092843.md) | [3,557](/filings/0000950170-24-122373.md) | [3,796](/filings/0001193125-26-046646.md) | [3,896](/filings/0000950170-25-067055.md) | [3,684](/filings/0000950170-25-104104.md) | [3,502](/filings/0001193125-25-267056.md) | [3,854](/filings/0001193125-26-335232.md) | [3,829](/filings/0001193125-26-212122.md) | [3,504](/filings/0001193125-26-335232.md) |
| Current liabilities | $m | [839](/filings/0000950170-23-061183.md) | [942](/filings/0000950170-25-018873.md) | [960](/filings/0000950170-24-057772.md) | [1,437](/filings/0000950170-24-092843.md) | [1,489](/filings/0000950170-24-122373.md) | [1,573](/filings/0001193125-26-046646.md) | [1,577](/filings/0000950170-25-067055.md) | [1,287](/filings/0000950170-25-104104.md) | [1,316](/filings/0001193125-25-267056.md) | [1,467](/filings/0001193125-26-335232.md) | [1,518](/filings/0001193125-26-212122.md) | [1,544](/filings/0001193125-26-335232.md) |
| Total liabilities | $m | [1,629](/filings/0000950170-23-061183.md) | [1,737](/filings/0000950170-25-018873.md) | [1,744](/filings/0000950170-24-057772.md) | [1,755](/filings/0000950170-24-092843.md) | [1,805](/filings/0000950170-24-122373.md) | [1,888](/filings/0001193125-26-046646.md) | [1,892](/filings/0000950170-25-067055.md) | [1,619](/filings/0000950170-25-104104.md) | [1,647](/filings/0001193125-25-267056.md) | [1,788](/filings/0001193125-26-335232.md) | [1,832](/filings/0001193125-26-212122.md) | [1,848](/filings/0001193125-26-335232.md) |
| Shareholders' equity | $m | [1,199](/filings/0000950170-24-122373.md) | [1,334](/filings/0001193125-26-046646.md) | [1,449](/filings/0001193125-25-267056.md) | [1,601](/filings/0001193125-25-267056.md) | [1,752](/filings/0001193125-25-267056.md) | [1,908](/filings/0001193125-26-335232.md) | [2,005](/filings/0001193125-26-335232.md) | [2,065](/filings/0001193125-26-335232.md) | [1,856](/filings/0001193125-25-267056.md) | [2,066](/filings/0001193125-26-335232.md) | [1,997](/filings/0001193125-26-335232.md) | [1,657](/filings/0001193125-26-335232.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [89.0 d](/filings/0000950170-24-122373.md) | [104 d](/filings/0001193125-26-046646.md) | [127](/filings/0000950170-25-067055.md) | [118 d](/filings/0000950170-25-104104.md) | [160 d](/filings/0001193125-25-267056.md) | [194 d](/filings/0001193125-26-046646.md) | [162](/filings/0001193125-26-212122.md) | [164 d](/filings/0001193125-26-335232.md) | [187 d](/filings/0001193125-25-267056.md) | [247 d](/filings/0001193125-26-046646.md) | [199](/filings/0001193125-26-212122.md) | [223 d](/filings/0001193125-26-335232.md) |
| Capital expenditure | $m | [10.8 d](/filings/0000950170-24-122373.md) | [8.7 d](/filings/0001193125-26-046646.md) | [5.9](/filings/0000950170-25-067055.md) | [8.2 d](/filings/0000950170-25-104104.md) | [11.1 d](/filings/0001193125-25-267056.md) | [12.7 d](/filings/0001193125-26-046646.md) | [13.3](/filings/0001193125-26-212122.md) | [16.0 d](/filings/0001193125-26-335232.md) | [10.3 d](/filings/0001193125-25-267056.md) | [13.5 d](/filings/0001193125-26-046646.md) | [15.4](/filings/0001193125-26-212122.md) | [19.7 d](/filings/0001193125-26-335232.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [360 d](/filings/0001193125-25-267056.md) | [14.7 d](/filings/0001193125-26-046646.md) | [207](/filings/0001193125-26-212122.md) | [536 d](/filings/0001193125-26-335232.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [48.1](/filings/0000950170-23-061183.md) | [49.4](/filings/0000950170-24-057772.md) | [49.7](/filings/0000950170-24-092843.md) | [50.1](/filings/0000950170-24-122373.md) | [51.5](/filings/0000950170-25-067055.md) | [51.0](/filings/0000950170-25-104104.md) | [51.8](/filings/0001193125-25-267056.md) | [52.2](/filings/0001193125-26-212122.md) | [52.7](/filings/0001193125-26-335232.md) | [52.7](/filings/0001193125-25-267056.md) | [52.6](/filings/0001193125-26-212122.md) | [50.6](/filings/0001193125-26-335232.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 49,866,201 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001193125-26-335232.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.